PL1776136T3 - Leczenie stanów związanych z demielinizacją - Google Patents

Leczenie stanów związanych z demielinizacją

Info

Publication number
PL1776136T3
PL1776136T3 PL05764255T PL05764255T PL1776136T3 PL 1776136 T3 PL1776136 T3 PL 1776136T3 PL 05764255 T PL05764255 T PL 05764255T PL 05764255 T PL05764255 T PL 05764255T PL 1776136 T3 PL1776136 T3 PL 1776136T3
Authority
PL
Poland
Prior art keywords
treatment
conditions involving
involving demyelination
demyelination
conditions
Prior art date
Application number
PL05764255T
Other languages
English (en)
Inventor
Sha Mi
R Blake Pepinsky
John Mccoy
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of PL1776136T3 publication Critical patent/PL1776136T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
PL05764255T 2004-06-24 2005-06-24 Leczenie stanów związanych z demielinizacją PL1776136T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58296604P 2004-06-24 2004-06-24
US61729704P 2004-10-07 2004-10-07
US62843504P 2004-11-15 2004-11-15
US68047505P 2005-05-13 2005-05-13
PCT/US2005/022881 WO2006002437A2 (en) 2004-06-24 2005-06-24 Treatment of conditions involving demyelination
EP05764255A EP1776136B1 (en) 2004-06-24 2005-06-24 Treatment of conditions involving demyelination

Publications (1)

Publication Number Publication Date
PL1776136T3 true PL1776136T3 (pl) 2013-03-29

Family

ID=35782388

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764255T PL1776136T3 (pl) 2004-06-24 2005-06-24 Leczenie stanów związanych z demielinizacją

Country Status (15)

Country Link
US (2) US8486893B2 (pl)
EP (2) EP1776136B1 (pl)
JP (2) JP4960865B2 (pl)
KR (1) KR101239542B1 (pl)
AU (1) AU2005258335B2 (pl)
BR (1) BRPI0512500A (pl)
CA (1) CA2572193A1 (pl)
DK (1) DK1776136T3 (pl)
ES (1) ES2395094T3 (pl)
HR (1) HRP20121061T1 (pl)
IL (1) IL180077A (pl)
PL (1) PL1776136T3 (pl)
PT (1) PT1776136E (pl)
RS (1) RS52593B (pl)
WO (1) WO2006002437A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
CA2631181A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
ATE502960T1 (de) * 2006-11-17 2011-04-15 Novartis Ag Lingo bindende moleküle und pharmazeutische verwendung davon
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101636168B (zh) * 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
DK2982695T3 (da) * 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
JP2015534564A (ja) 2012-10-09 2015-12-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄障害の治療のための併用療法および使用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
BR112021017644A2 (pt) 2019-03-11 2021-11-16 Biogen Ma Inc Composições farmacêuticas contendo anticorpos anti-lingo-1

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5532351A (en) 1990-07-12 1996-07-02 Arch Development Corporation Nucleic acid sequences encoding OMGP
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995014930A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. Kinase receptor activation assay
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE4415539C2 (de) 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
HU226980B1 (en) 1994-10-25 2010-04-28 Toyama Chemical Co Ltd Use of 1,2-ethanediol derivatives or salts thereof for the preparation of pharmaceutical compositions having nerve growth factor (nfg) potentiator activity
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6280964B1 (en) 1995-04-14 2001-08-28 The Regents Of The University Of California Binding sites for phosphotyrosine binding domains
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
IT235676Y1 (it) 1995-07-27 2000-07-12 Felice Gaudioso Allestimenti per lo svolgimento del gioco wormhole action match.
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
JP2000501416A (ja) 1996-04-26 2000-02-08 ユニバーシティー オブ オタワ ニューロン病を治療し予防するための、治療法および薬物のスクリーニング法
PT912184E (pt) 1996-06-25 2002-12-31 Cephalon Inc Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
IL127872A0 (en) 1996-07-19 1999-10-28 Amgen Inc Analogs of cationic proteins
BR9712978A (pt) 1996-09-11 2000-04-18 Gen Hospital Corp Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada
US6261545B1 (en) 1996-09-13 2001-07-17 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20070213290A1 (en) 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999004705A1 (en) 1997-07-25 1999-02-04 Tsui Ban C H Devices, systems and methods for determining proper placement of epidural catheters
AU8768798A (en) 1997-08-04 1999-02-22 Millennium Pharmaceuticals, Inc. Tango-78, tango-79, and tango-81 nucleic acid molecules and polypeptides
US20020112251A1 (en) 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
EP1205546B1 (en) 1997-10-24 2005-11-23 Genentech, Inc. Polypeptide and nucleic acids encoding the same
FR2776661B1 (fr) 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
AU5922999A (en) 1998-09-16 2000-04-03 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ304224B6 (cs) 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
WO2001009318A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
JP2003527089A (ja) * 1999-08-17 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド 膜関連タンパク質
US6461414B1 (en) 1999-10-29 2002-10-08 Baker Hughes Incorporated Foam monitoring and control system
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US20040252299A9 (en) * 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
IL150566A0 (en) 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
DE60123399T2 (de) 2000-01-18 2007-08-23 The Texas A & M University System, College Station Pharmazeutische zubereitungen enthaltend beta-turn peptidomimetische zyklische substanzen
WO2001055333A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
CA2393616A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2395872A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059063A2 (en) 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2399652A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Methods and materials relating to neuronal guidance molecule-like (ngm-like) polypeptides and polynucleotides
US6800607B2 (en) 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6430914B1 (en) 2000-06-29 2002-08-13 Foster Wheeler Energy Corporation Combined cycle power generation plant and method of operating such a plant
US20040010118A1 (en) 2000-08-16 2004-01-15 Zerhusen Bryan D. Novel proteins and nucleic acids encoding same
AU9261901A (en) 2000-09-13 2002-03-26 Smithkline Beecham Corp Novel compounds
WO2002029058A2 (en) 2000-10-05 2002-04-11 Curagen Corporation Human proteins, polynucleotides encoding them and methods of using the same
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP1338198B1 (en) 2000-12-01 2007-11-28 Central Institute For Experimental Animals Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
US20030216558A1 (en) 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
CA2448073A1 (en) 2001-06-04 2002-12-12 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030162734A1 (en) 2001-06-28 2003-08-28 Miller Carol A. Modulation of DENN-MADD expression and interactions for treating neurological disorders
US7223558B2 (en) 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050123990A1 (en) 2001-09-26 2005-06-09 Incyte Corporation Membrane associated proteins
AU2002365258A1 (en) 2001-10-12 2003-09-02 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2003035833A2 (en) 2001-10-22 2003-05-01 Exelixis, Inc. Modifier of the p53 pathway and methods of use
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US20030215849A1 (en) 2002-03-01 2003-11-20 Marcia Belvin PDPK1s as modifiers of the p53 pathway and methods of use
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7077522B2 (en) 2002-05-03 2006-07-18 University Of Rochester Sharpness metric for vision quality
US6794785B2 (en) 2002-06-26 2004-09-21 Denso Corporation Alternator for vehicles
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
WO2005016955A2 (en) 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20070275871A1 (en) 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
JP2007527712A (ja) 2004-02-12 2007-10-04 レキシコン・ジェネティクス・インコーポレーテッド 新規な遺伝子破壊、これに関する組成物と方法
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US20060009288A1 (en) 2004-07-07 2006-01-12 Devos John A Conveying information to an interrogator using resonant and parasitic radio frequency circuits
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR054260A1 (es) 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
WO2006119013A2 (en) 2005-04-29 2006-11-09 Wyeth Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
US8309517B2 (en) 2005-05-16 2012-11-13 Mcgill University LGI, LINGO and p75NTR family members: novel modulators of neuronal growth
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
WO2006133353A2 (en) 2005-06-08 2006-12-14 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
JP2008543790A (ja) 2005-06-16 2008-12-04 ユニバーシティー・テクノロジーズ・インターナショナル・インコーポレイテッド 短腸症候群の治療
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1940460A4 (en) 2005-10-27 2009-08-12 Biogen Idec Inc OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
CA2631181A1 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
US20070186296A1 (en) 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
CN101405297A (zh) 2006-02-03 2009-04-08 惠氏公司 Lingo-1结构
WO2007098283A2 (en) 2006-02-27 2007-08-30 Biogen Idec Ma Inc. Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
ATE502960T1 (de) 2006-11-17 2011-04-15 Novartis Ag Lingo bindende moleküle und pharmazeutische verwendung davon
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2702630C (en) 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
CN102171247A (zh) 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-α拮抗剂多靶点结合蛋白
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
WO2010056374A2 (en) 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
FR2958293B1 (fr) 2010-04-01 2014-09-26 Centre Nat Rech Scient Outils pour l'identification de ligands de lingo-1,lingo-2, lingo-3 et lingo-4, et utilisations
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂

Also Published As

Publication number Publication date
WO2006002437A3 (en) 2006-12-28
AU2005258335B2 (en) 2011-03-17
IL180077A (en) 2014-02-27
JP2012072193A (ja) 2012-04-12
IL180077A0 (en) 2007-05-15
KR101239542B1 (ko) 2013-03-07
EP1776136B1 (en) 2012-10-03
EP1776136A2 (en) 2007-04-25
BRPI0512500A (pt) 2008-03-11
AU2005258335A1 (en) 2006-01-05
DK1776136T3 (da) 2012-12-03
CA2572193A1 (en) 2006-01-05
US9068992B2 (en) 2015-06-30
PT1776136E (pt) 2012-12-05
WO2006002437A2 (en) 2006-01-05
HRP20121061T1 (hr) 2013-01-31
KR20070050913A (ko) 2007-05-16
ES2395094T3 (es) 2013-02-08
RS52593B (sr) 2013-04-30
US8486893B2 (en) 2013-07-16
HK1103978A1 (en) 2008-01-04
JP4960865B2 (ja) 2012-06-27
US20130273558A1 (en) 2013-10-17
US20060009388A1 (en) 2006-01-12
EP1776136A4 (en) 2009-12-09
EP2474317A1 (en) 2012-07-11
JP2008504297A (ja) 2008-02-14

Similar Documents

Publication Publication Date Title
IL180077A0 (en) Treatment of conditions involving demyelination
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
GB0404656D0 (en) Treatment of spinal conditions
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GB0518508D0 (en) Treatment of waste
GB0415181D0 (en) Compounds for use in the treatment of infection
GB0426196D0 (en) Methods of treatment
EP1793813A4 (en) TREATMENT OF HYPERACTIVITY DISORDER WITH DEFICIT ATTENTION (ADHD)
SI1776136T1 (sl) Zdravljenje stanj, ki vključujejo demielinizacijo
GB0410379D0 (en) Treatment of cancer
GB0423273D0 (en) Treatment of cancer
ZA200606780B (en) Compounds for the treatment of diseases
HU0400952D0 (en) Treatment of anus-cancer
GB0422012D0 (en) Methods of treatment
GB0602857D0 (en) The treatment of sialorrhoea
GB0518003D0 (en) Treatment of hepatatis c
GB0417867D0 (en) Treatment of pipes
GB0412416D0 (en) Treatment of incontinence
GB0410846D0 (en) Treatment of neurodegenerative conditions
GB2445888B (en) Treatment of hypertension
TJ20050863A (en) The way of narcotism treatment
GB0422225D0 (en) Treatment of cancer
GB0420845D0 (en) Treatment of cancer
GB0421734D0 (en) Treatment of cancer